ALL-287: Acute Lymphoblastic Leukemia: Clinical Characteristics and Survival in a Private Health Care Program Population in Argentina

Context: Acute lymphoblastic leukemia (ALL) comprises 85% compared to 50%. Available ALL data is mainly from pediatric populations in European countries and the United States. Argentinian data is scarce. Objective: Describe clinical characteristics and survival in ALL patients. Design: Retrospective cohort study between January 1, 2010, and December 31, 2019. Setting: The study was conducted at Hospital Italiano de Buenos Aires. Patients: All adult and pediatric patients in the Italian Hospital Medical Program with ALL according to WHO criteria were included. Main Outcome Measures: Survival time was estimated one year from diagnosis, expressed as one-year follow-up. Fatality rate was calculated as incident cases per 100 person-years. An age-stratified analysis was performed. Results: 22 patients with ALL were included. The median age at diagnosis was 43.22 years (IQR: 10.35–75.45), 54.55% were male. Considering the WHO classification, 18 (81.82%) were ALL not otherwise specified. By immunophenotype, 16 (72.73%) corresponded to common B-ALL. Chromosome Ph-positive was seen in 13.64%. Complex karyotype only occurred in the adult subgroup (18 years or older). In stratified analysis, 36.36% of patients were diagnosed younger than 18 years (pediatric population), and 31.81% of patients were diagnosed at age 65 years or older (adult population). Only 1 patient was in the AYA subgroup (15–40 years). The median follow-up for the pediatric population was 6.74 years (IQR: 4.42–9.54) vs 1.08 years (IQR: 0.84–1.97) in adults. The fatality rate in pediatric cases was 18 per 100 person-years (95% CI: 0.2–13) vs 44.65 (95% CI: 23.23–85.81) in adults. Only one patient died among those younger than 17 years vs 9 (64.28%) among those older than 18 years. All patients up to 17 years of age were alive at one-year follow-up, unlike adults, who had a one-year survival rate of 64% (95% CI 34%–83%). Conclusions: Our outcomes are similar to data in the literature, with a better prognosis and survival among the population aged 17 years or younger. We do not have data on patients in the AYA subgroup.